Details of the Drug

General Information of Drug (ID: DMM549D)

Drug Name
IMO-3100
Indication
Disease Entry ICD 11 Status REF
Psoriasis vulgaris EA90 Phase 2 [1]
Autoimmune diabetes 5A10 Phase 1 [2]
Cross-matching ID
TTD ID
D08OXU
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Toll-like receptor 7 (TLR7) TTRJ1K4 TLR7_HUMAN Modulator [3]
Toll-like receptor 9 (TLR9) TTSHG0T TLR9_HUMAN Modulator [3]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Psoriasis vulgaris
ICD Disease Classification EA90
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Toll-like receptor 7 (TLR7) DTT TLR7 3.32E-25 0.44 0.88
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 ClinicalTrials.gov (NCT01622348) Trial of IMO-3100 in Patients With Moderate to Severe Plaque Psoriasis. U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of Idera Pharmaceuticals (2011).
3 Company report (Iderapharma)